FCMI
TVTX icon

Foresite Capital Management IV’s Travere Therapeutics TVTX Stock Holding History

Foresite Capital Management IV’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-30,000
Closed -$612K – 18
2020
Q2 		$612K Buy
+30,000
New +$478K 0.3% 12

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Foresite Capital Management IV's TVTX Position: Q3 2020 in Review

Foresite Capital Management IV sold out of Travere Therapeutics (TVTX) in Q3 2020, closing a stake of 30,000 shares — an estimated $612K sold.

Foresite Capital Management IV first reported a position in TVTX in Q2 2020 and held it in 1 quarter. The position peaked at $612K in Q2 2020. 134 funds tracked by Wall St. Rank hold TVTX as of Q3 2020.

  • Foresite Capital Management IV reported no remaining Travere Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Foresite Capital Management IV sold 30,000 Travere Therapeutics shares in Q3 2020, an estimated $612K.
  • Foresite Capital Management IV first reported a position in Travere Therapeutics in Q2 2020 and held it in 1 quarter.
  • Foresite Capital Management IV's Travere Therapeutics position peaked at $612K in Q2 2020.
  • 134 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2020.

Based on Foresite Capital Management IV's 13F filing for Q3 2020, filed 13 Nov 2020.